Key Insights

Highlights

Success Rate

83% trial completion

Published Results

35 trials with published results (12%)

Research Maturity

101 completed trials (35% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

7.2%

21 terminated out of 291 trials

Success Rate

82.8%

-3.7% vs benchmark

Late-Stage Pipeline

4%

12 trials in Phase 3/4

Results Transparency

35%

35 of 101 completed with results

Key Signals

35 with results83% success21 terminated

Data Visualizations

Phase Distribution

206Total
Not Applicable (113)
Early P 1 (10)
P 1 (30)
P 2 (41)
P 3 (11)
P 4 (1)

Trial Status

Completed101
Recruiting77
Active Not Recruiting33
Terminated21
Withdrawn21
Unknown18

Trial Success Rate

82.8%

Benchmark: 86.5%

Based on 101 completed trials

Clinical Trials (291)

Showing 20 of 20 trials
NCT07644702Not ApplicableRecruitingPrimary

WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial Participation for Rural and Low Income Women

NCT05557877Phase 2RecruitingPrimary

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

NCT05178498Recruiting

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT00991094RecruitingPrimary

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

NCT05226663Phase 2Active Not RecruitingPrimary

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

NCT05132296Not ApplicableActive Not RecruitingPrimary

Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer

NCT06995898Not ApplicableRecruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT07619534Not Yet Recruiting

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

NCT07067138Not ApplicableSuspended

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT06130826Phase 1SuspendedPrimary

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

NCT07038369Phase 1Active Not Recruiting

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT06274034Early Phase 1RecruitingPrimary

MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors

NCT06783179RecruitingPrimary

Postoperative Outcomes and Patient Satisfaction With Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement

NCT05505175Completed

Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

NCT07076147RecruitingPrimary

Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer

NCT07474090Not ApplicableActive Not Recruiting

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial

NCT07606287Not ApplicableNot Yet RecruitingPrimary

Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital

NCT05787834Not ApplicableRecruitingPrimary

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer

NCT07216274Not ApplicableCompletedPrimary

Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer

Scroll to load more

Research Network

Activity Timeline